Is Oculis Holding AG (OCS) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2025
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.1% / 30% | 6.3% / 30% | 0.0% / 30% | N/A | ✓ HALAL |
| DJIM | 0.1% / 33% | 6.3% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 1.0% / 33% | 82.0% / 33% | 0.6% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.1% / 33% | 6.3% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 1.0% / 33% | 82.0% / 33% | 0.6% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | -5020.2% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -73.5% | |
| Return on Assets (ROA) | -28.7% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$66M |
| Free Cash Flow | -$68M |
| Total Debt | $2M |
| Debt-to-Equity | 1.2 |
| Current Ratio | 6.0 |
| Total Assets | $236M |
Price & Trading
| Last Close | $24.99 |
| 50-Day MA | $27.34 |
| 200-Day MA | $21.16 |
| Avg Volume | 319K |
| Beta | 0.1 |
|
52-Week Range
$14.00
| |
About Oculis Holding AG (OCS)
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Oculis Holding AG (OCS) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Oculis Holding AG is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Oculis Holding AG's debt ratio?
Oculis Holding AG's debt ratio is 0.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 1.0%.
What are Oculis Holding AG's key financial metrics?
Oculis Holding AG has a market capitalization of $1.4B. Return on equity stands at -73.5%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.